NasdaqHealth CareBiological Products, (No Diagnostic Substances)NEW YORK, NY

MiNK Therapeutics, Inc. INKT

Ask your AI

Estimated market cap $47.95M5.13M shares, shares as of Nov 6, 2026CIK 1840229

Insider trades, 12 mo

0 buys · 8 sells

$46.6K sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

3.8% of shares · 3 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in MiNK Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 12, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in MiNK Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

8 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Jun 4, 2026. Insiders have two business days to file.

Recent insider trades

Barbara Ryan Director	Jun 4 Form 4 ↗	Sale	−$6,340 500 sh @ $12.68	-26.4%
Barbara Ryan Director	Jun 4 Form 4 ↗	Sale	−$12.8K 1,000 sh @ $12.80	-26.4%
Barbara Ryan Director	Mar 10 Form 4 ↗	Sale	−$7,785 500 sh @ $15.57	-42.3%
Barbara Ryan Director	Mar 10 Form 4 ↗	Sale	−$7,650 500 sh @ $15.30	-42.3%
Barbara Ryan Director	Mar 10 Form 4 ↗	Sale	−$4,584 300 sh @ $15.28	-42.3%

All INKT insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

192,980 shares

21 funds report INKT. Values checked against market prices.

Funds own 4.3% of shares (Q2 2026)

29 funds hold the stock.

Q3 2026: 3.8% · 5,560 of ~8,900 funds reported so far

Q2 20251.4%
Q3 20252.2%
Q4 20253.5%
Q1 20262.8%
Q2 20264.3%
Q3 2026 (so far)3.8%

Q3 2026. 0 new, 3 added to, 4 trimmed, 8 exited since Q2 2026.

Top 13F holders
#
1	Vanguard Capital Management LLC 13F ↗	68,452	$859.1K	-0.3%
2	DNB Asset Management AS 13F ↗	43,960	$551.7K	-20.3%
3	Geode Capital Management, LLC 13F ↗	18,759	$235.5K	+20.5%
4	Longbow Finance SA 13F ↗	16,667	$209.2K	unchanged
5	Vanguard Fiduciary Trust Co 13F ↗	13,164	$165.2K	+58.9%
6	BlackRock, Inc. 13F ↗	13,074	$164.1K	-2.3%
7	Bolton Securities Corporation 13F ↗	13,000	$163.2K	unchanged
8	Steward Partners Investment Advisory, LLC 13F ↗	2,000	$25.1K	unchanged
9	US Bancorp 13F ↗	1,995	$25.0K	unchanged
10	UBS Group AG 13F ↗	1,462	$18.3K	-70.1%

Download CSV Every fund that holds INKT, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What MiNK Therapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What MiNK Therapeutics, Inc. and its lobbying firms report each quarter.

Loading…

H-1B labor applications at MiNK Therapeutics, Inc.

0 certified in 12 mo

Labor condition applications decided by the Department of Labor, matched to MiNK Therapeutics, Inc. by employer name. An application is not a hire.

Median yearly wage offered, full-time certified applications, Jul 2025 to Jun 2026: —

H-1B labor applications decided at MiNK Therapeutics, Inc. by quarter
Quarter	Certified	All decided	Workers asked for
2024 Q3	0	0	0
2024 Q4	0	2	0
2025 Q1	0	0	0
2025 Q2	0	0	0
2025 Q3	0	0	0
2025 Q4	0	0	0
2026 Q1	0	0	0
2026 Q2	0	0	0

All INKT applications

We match the employer's name to a public company automatically, including a reviewed list of subsidiaries. A subsidiary can be missed and a similar name can be matched wrongly. The files carry no worker names.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q1 2025	16	—	46,305	$400.2K
Q2 2025	19	+3	61,922	$460.8K
Q3 2025	19	0	104,322	$1.5M
Q4 2025	25	+6	166,052	$1.9M
Q1 2026	24	-1	139,832	$1.5M
Q2 2026	29	+5	217,425	$2.5M
Q3 2026	21	-8	192,980	$2.4M

Each point is a quarter-end, from Q1 2025 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (603693201). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2025) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakesNone in 12 mo 8-K events1 in 90 days Patents1 patent granted Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 1 in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials1 active IPO history1 registration Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: MiNK Therapeutics, Inc.
Address: 149 FIFTH AVENUE, SUITE 500, NEW YORK, NY 10010
Phone: 212-994-8250
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company, emerging growth company
Incorporated in: DE
Listed as: INKT (Nasdaq)
Former names: AgenTus Therapeutics, Inc. (until 2021); AgenTus Therapeutics, Inc. (until 2021)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$9.34−$0.19 (−1.99%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $9.34 · High $11.04Nov 13, 2026

Aug 13, 2026Low $9.34 · High $12.73Nov 13, 2026

Nov 13, 2025Low $8.56 · High $14.21Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.